718 related articles for article (PubMed ID: 28427296)
1. Predictors of response to therapy with omalizumab in patients with severe allergic asthma - a real life study.
Kallieri M; Papaioannou AI; Papathanasiou E; Ntontsi P; Papiris S; Loukides S
Postgrad Med; 2017 Aug; 129(6):598-604. PubMed ID: 28427296
[TBL] [Abstract][Full Text] [Related]
2. Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab.
Suzukawa M; Matsumoto H; Ohshima N; Tashimo H; Asari I; Tajiri T; Niimi A; Nagase H; Matsui H; Kobayashi N; Shoji S; Ohta K
Respir Med; 2018 Jan; 134():95-102. PubMed ID: 29413515
[TBL] [Abstract][Full Text] [Related]
3. RANTES in exhaled breath condensate of patients with severe persistent allergic asthma during omalizumab therapy.
Zietkowski Z; Skiepko R; Tomasiak-Lozowska MM; Lenczewska D; Bodzenta-Lukaszyk A
Int Arch Allergy Immunol; 2011; 154(1):25-32. PubMed ID: 20664274
[TBL] [Abstract][Full Text] [Related]
4. Omalizumab Is Equally Effective in Persistent Allergic Oral Corticosteroid-Dependent Asthma Caused by Either Seasonal or Perennial Allergens: A Pilot Study.
Domingo C; Pomares X; Navarro A; Rudi N; Sogo A; Dávila I; Mirapeix RM
Int J Mol Sci; 2017 Feb; 18(3):. PubMed ID: 28264494
[TBL] [Abstract][Full Text] [Related]
5. High serum free IL-18 is associated with decreased omalizumab efficacy: findings from a 2-year omalizumab treatment study.
Morimoto C; Matsumoto H; Tajiri T; Gon Y; Ito R; Hashimoto S; Suzukawa M; Ohta K; Izuhara K; Ono J; Ohta S; Ito I; Oguma T; Kanemitsu Y; Nagasaki T; Izuhara Y; Niimi A; Hirai T
J Asthma; 2021 Sep; 58(9):1133-1142. PubMed ID: 32375555
[TBL] [Abstract][Full Text] [Related]
6. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma.
Djukanović R; Wilson SJ; Kraft M; Jarjour NN; Steel M; Chung KF; Bao W; Fowler-Taylor A; Matthews J; Busse WW; Holgate ST; Fahy JV
Am J Respir Crit Care Med; 2004 Sep; 170(6):583-93. PubMed ID: 15172898
[TBL] [Abstract][Full Text] [Related]
7. Longterm clinical outcomes of omalizumab therapy in severe allergic asthma: Study of efficacy and safety.
Mansur AH; Srivastava S; Mitchell V; Sullivan J; Kasujee I
Respir Med; 2017 Mar; 124():36-43. PubMed ID: 28284319
[TBL] [Abstract][Full Text] [Related]
8. Ratio of plasma IL-13/TNF- ∝ and CXCL10/CCL17 predicts mepolizumab and omalizumab response in asthma better than eosinophil count or immunoglobulin E level.
Akenroye A; Nopsopon T; Hacker JJ; Laidlaw TM
Sci Rep; 2024 May; 14(1):10404. PubMed ID: 38710930
[TBL] [Abstract][Full Text] [Related]
9. The effect of omalizumab on eosinophilic inflammation of the respiratory tract in patients with allergic asthma.
Kupryś-Lipińska I; Molińska K; Kuna P
Pneumonol Alergol Pol; 2016; 84(4):232-43. PubMed ID: 27435350
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Study on the Association of Biomarkers With Real-world Outcomes of Omalizumab-treated Patients With Allergic Asthma.
Kavati A; Zhdanava M; Ortiz B; Lecocq J; Schiffman B; Pilon D; Ho H; Lefebvre P; Stone B
Clin Ther; 2019 Oct; 41(10):1956-1971. PubMed ID: 31563391
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers for severe allergic asthma in children: could they be useful to guide disease control and use of omalizumab?
Amat F; Labbé A
Expert Rev Respir Med; 2018 Jun; 12(6):475-482. PubMed ID: 29741411
[TBL] [Abstract][Full Text] [Related]
12. Utility of serum periostin and free IgE levels in evaluating responsiveness to omalizumab in patients with severe asthma.
Tajiri T; Matsumoto H; Gon Y; Ito R; Hashimoto S; Izuhara K; Suzukawa M; Ohta K; Ono J; Ohta S; Ito I; Oguma T; Inoue H; Iwata T; Kanemitsu Y; Nagasaki T; Niimi A; Mishima M
Allergy; 2016 Oct; 71(10):1472-9. PubMed ID: 27113353
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive efficacy of omalizumab for severe refractory asthma: a time-series observational study.
Tajiri T; Niimi A; Matsumoto H; Ito I; Oguma T; Otsuka K; Takeda T; Nakaji H; Inoue H; Iwata T; Nagasaki T; Kanemitsu Y; Izuhara Y; Mishima M
Ann Allergy Asthma Immunol; 2014 Oct; 113(4):470-5.e2. PubMed ID: 24994694
[TBL] [Abstract][Full Text] [Related]
14. Monitoring free serum IgE in severe asthma patients treated with omalizumab.
Korn S; Haasler I; Fliedner F; Becher G; Strohner P; Staatz A; Taube C; Buhl R
Respir Med; 2012 Nov; 106(11):1494-500. PubMed ID: 22884459
[TBL] [Abstract][Full Text] [Related]
15. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
Ledford D; Busse W; Trzaskoma B; Omachi TA; Rosén K; Chipps BE; Luskin AT; Solari PG
J Allergy Clin Immunol; 2017 Jul; 140(1):162-169.e2. PubMed ID: 27826098
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of omalizumab in non-allergic severe asthma.
Domingo C; Pomares X; Angril N; Rudi N; Amengual MJ; Mirapeix RM
J Biol Regul Homeost Agents; 2013; 27(1):45-53. PubMed ID: 23489686
[TBL] [Abstract][Full Text] [Related]
17. Association of upper and lower airway eosinophilic inflammation with response to omalizumab in patients with severe asthma.
Kurokawa M; Koya T; Takeuchi H; Hayashi M; Sakagami T; Ishioka K; Gon Y; Hasegawa T; Kikuchi T
J Asthma; 2020 Jan; 57(1):71-78. PubMed ID: 30489179
[No Abstract] [Full Text] [Related]
18. Omalizumab lowers asthma exacerbations, oral corticosteroid intake and blood eosinophils: Results of a 5-YEAR single-centre observational study.
Pelaia C; Calabrese C; Barbuto S; Busceti MT; Preianò M; Gallelli L; Savino R; Vatrella A; Pelaia G
Pulm Pharmacol Ther; 2019 Feb; 54():25-30. PubMed ID: 30414440
[TBL] [Abstract][Full Text] [Related]
19. [Analysis of predictors of response to anti-IgE therapy in patients with severe atopic bronchial asthma in real clinical practice].
Fomina DS; Mukhina OA; Lebedkina MS; Gadzhieva MK; Bobrikova EN; Sinyavkin DO; Parshin VV; Chernov AA; Belevskiy AS
Ter Arkh; 2022 Mar; 94(3):413-419. PubMed ID: 36286907
[TBL] [Abstract][Full Text] [Related]
20. Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.
Latorre M; Bacci E; Seccia V; Bartoli ML; Cardini C; Cianchetti S; Cristofani L; Di Franco A; Miccoli M; Puxeddu I; Celi A; Paggiaro P
Ther Adv Respir Dis; 2020; 14():1753466620965151. PubMed ID: 33263506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
